Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00612976 |
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine assessments, the participating physicians (i.e.general practitioners and internists) are asked to document relevant data related to the budesonide/formoterole therapy in patients with COPD.
Condition |
---|
Pulmonary Disease, Chronic Obstructive |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | Symbicort in Chronic Obstruktive Pulmonary Disease |
Enrollment: | 18014 |
Study Start Date: | February 2006 |
Primary Completion Date: | September 2006 (Final data collection date for primary outcome measure) |
Groups/Cohorts |
---|
1
Patients with COPD treated with budesonide/formoterol
|
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
general practitioners and internists
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | AstraZeneca Germany ( Dr Kai Richter ) |
Study ID Numbers: | 1312006001, budesonide /formoterol, German PMS trial no.8 |
Study First Received: | January 30, 2008 |
Last Updated: | February 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00612976 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
treatment of COPD documentation of relevant data related to the budesonide/formoterole therapy in patients with COPD. |
Lung Diseases, Obstructive Symbicort Respiratory Tract Diseases Lung Diseases |
Respiration Disorders Budesonide Chronic Disease Pulmonary Disease, Chronic Obstructive |
Disease Attributes Pathologic Processes |